Global HER2 Targeting ADC Drugs Market Strategic Research Report

Scope of the Report

The global HER2 Targeting ADC Drugs market size is predicted to grow from US$ 7,811 million in 2025 to US$ 14,054 million in 2032; it is expected to grow at a CAGR of 8.5% from 2026 to 2032.

In 2025, global HER2 Targeting ADC Drugs reached approximately 6.99 M Units, with an average global market price of around 1143 USD per Unit.

HER2 Targeting ADC Drugs (HER2-targeted antibody–drug conjugates) are a class of targeted cancer medicines that use an anti-HER2 monoclonal antibody to recognize and bind tumor cells with HER2 overexpression, amplification, or certain HER2-driven biology, and then deliver a highly potent cytotoxic payload into (and sometimes around) those cells. Structurally, they are built from three essential parts: (1) the HER2 antibody (the “homing” component), (2) a chemical linker (designed to be stable in blood but release the payload under specific conditions), and (3) the payload (a cell-killing drug such as a microtubule inhibitor or topoisomerase I inhibitor). After binding HER2, the ADC is typically internalized and processed so the payload can be released to damage critical cellular machinery and trigger cancer cell death; depending on the payload/linker properties, some HER2 ADCs can also produce a bystander effect, meaning the released payload may diffuse to kill nearby tumor cells that have lower HER2 expression.

HER2 Targeting ADC Drugs fuse the validated targeting precision of anti-HER2 antibodies with the tumor-killing power of highly potent payloads, offering a pragmatic way to overcome two persistent oncology pain points at once: the limited durability of benefit from many standard targeted agents once resistance emerges, and the systemic toxicity that often constrains conventional chemotherapy. By using HER2 as a delivery address, these conjugates can concentrate cytotoxic exposure inside cancer cells and—depending on linker and payload design—extend activity into heterogeneous tumors through bystander killing, which is increasingly important as clinicians recognize that clinically meaningful HER2 biology exists beyond the classic “HER2-positive” bucket. Looking forward, the category’s market potential is supported by broad applicability across major solid tumors, steady innovation that improves therapeutic index through smarter linkers, controlled conjugation, and next-generation payloads, and the likelihood that HER2 ADCs will become central “backbone” options that can be sequenced with, or paired alongside, endocrine therapy, immunotherapy, and other targeted agents—positioning the space for sustained expansion without relying on unrealistic expectations.

The core raw materials for HER2 Targeting ADC Drugs mainly include anti-HER2 antibodies, linkers, and auxiliary materials. Typical suppliers include Roche, Daiichi Sankyo, Merck, Thermo Fisher, etc. The downstream applications are mainly in the treatment of diseases such as breast cancer.

The production capacity of HER2 Targeting ADC Drugs varies greatly depending on the antibody production, conjugation process, quality control, and supply chain support. The gross profit margin of HER2 Targeting ADC Drugs is in the range of 70%-80%.

Global key HER2 Targeting ADC Drugs players cover Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global HER2 Targeting ADC Drugs market?

What factors are driving HER2 Targeting ADC Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do HER2 Targeting ADC Drugs market opportunities vary by end market size?

How does HER2 Targeting ADC Drugs break out by Type, by Application?

This report presents a comprehensive overview of the global HER2 Targeting ADC Drugs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Trastuzumab Type
• Non-trastuzumab Type

Segment by HER2 Expression Level

• HER2 Positive
• HER2 Low Expression

Segment by Antibody

• Monoclonal Antibody
• Bispecific Antibody
• Others

Segment by Application

• Breast Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global HER2 Targeting ADC Drugs market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Breast Cancer, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact